Skip to main content

Table 1 Tumour and normal tissue biodistribution (BOD) of radioimmunoconjugates in NRG mice with s.c. HNSCC primary xenografts a

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

  [64Cu]Cu-DOTA-panitumumab F(ab´)2   [177Lu]Lu-DOTA-panitumumab F(ab´)2 [177Lu]Lu-DOTA-trastuzumab F(ab’)2
       Percent injected dose/g (%ID/g)
Time p.i.: 6 h P-
value b
24 h P-value b P-value c 48 h P-value b 6 h 24 h P-value c 48 h 24 h
Heart 3.5 ± 0.5 n.s. 2.8 ± 0.3 n.s. 0.04 1.5 ± 0.1 n.s. 4.4 ± 0.2 2.9 ± 0.05 0.04 1.5 ± 0.5 1.3 ± 0.2
Lungs 3.9 ± 0.2 n.s. 3.4 ± 0.2 n.s. 0.04 2.4 ± 0.0 0.03 5.2 ± 0.6 2.1 ± 0.3 0.04 1.3 ± 0.0 1. 1 ± 0.1
Stomach 1.5 ± 0.1 n.s. 1.8 ± 0.1 n.s. 0.04 1.5 ± 0.1 0.03 1.8 ± 0.1 1.4 ± 0.0 0.04 0.8 ± 0.1 0.4 ± 0.05
Pancreas 1.0 ± 0.1 n.s. 1.2 ± 0.2 n.s. n.s. 1.2 ± 0.2 0.03 1.2 ± 0.2 1.0 ± 0.1 n.s. 0.6 ± 0.1 0.5 ± 0.2
Intestine 1.2 ± 0.0 n.s. 1.7 ± 0.1 n.s. 0.04 1.5 ± 0.1 0.03 1.9 ± 0.1 1.3 ± 0.1 0.04 1.0 ± 0.1 0.4 ± 0.07
Spleen 2.4 ± 0.1 n.s. 3.5 ± 0.3 n.s. n.s. 4.0 ± 0.7 n.s. 3.3 ± 0.1 4.3 ± 0.6 n.s. 3.8 ± 0.4 5.9 ± 1.4
Liver 8.4 ± 0.8 n.s. 7.5 ± 1.0 n.s. n.s. 6.2 ± 0.1 0.03 10.1 ± 1.6 12.1 ± 1.1 0.04 11.0 ± 0.9 8.0 ± 1.0
Kidneys 5.5 ± 0.2 n.s. 4.7 ± 0.5 n.s. 0.04 3.0 ± 0.2 n.s. 8.1 ± 0.5 5.9 ± 0.0 0.04 4.1 ± 0.4 27.4 ± 2.7
Bone 1.0 ± 0.3 n.s. 0.6 ± 0.1 n.s. n.s. 0.6 ± 0.1 n.s. 1.2 ± 0.1 1.8 ± 0.7 n.s. 0.6 ± 0.0 2.6 ± 1.6
Skin 1.0 ± 0.3 n.s. 2.7 ± 1.2 n.s. n.s. 1.0 ± 0.1 0.03 2.0 ± 0.3 2.2 ± 0.7 n.s. 1.6 ± 0.1 0.9 ± 0.2
Muscle 0.6 ± 0.1 n.s. 0.4 ± 0.1 n.s. n.s. 0.4 ± 0.0 0.03 0.7 ± 0.1 0.6 ± 0.1 n.s. 0.5 ± 0.0 0.3 ± 0.07
Blood 10.6 ± 0.6 n.s. 4.8 ± 0.3 n.s. 0.04 1.9 ± 0.1 0.03 15.3 ± 0.6 4.5 ± 0.1 0.04 1.1 ± 0.2 1.3 ± 0.3
Tumour 9.3 ± 1.0 n.s. 14.9 ± 1.1 n.s. 0.04 9.8 ± 1.3 n.s. 10.4 ± 2.0 18.0 ± 0.4 0.04 15.3 ± 2.6 2.6 ± 0.5
T/B Ratio d 0.9 ± 0.1 n.s. 3.1 ± 0.1 n.s. n.s. 5.1 ± 0.8 0.03 0.7 ± 0.1 4.0 ± 0.1 n.s. 14.7 ± 2.8 2.2 ± 0.6
  1. a[64Cu]Cu-DOTA-panitumumab F(ab´)2 (5.5–14.0 MBq; 50 μg) or [177Lu]Lu-DOTA-panitumumab F(ab´)2 (6.5 MBq; 50 μg) were injected i.v. (tail vein) in groups (n = 3–4) of tumour-bearing NRG mice
  2. bP-value for comparison of [64Cu]Cu-DOTA-panitumumab F(ab´)2 and [177Lu]Lu-DOTA-panitumumab F(ab´)2 at the same time point (6, 24 or 48 h) post-injection using a Mann-Whitney U test
  3. cP-value for comparison of [64Cu]Cu-DOTA-panitumumab F(ab´)2 or [177Lu]Lu-DOTA-panitumumab F(ab´)2 to [177Lu]Lu-DOTA-trastuzumab F(ab´)2 at 24 h p.i. using a Mann-Whitney U test
  4. dT/B: tumour:blood